Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting

MISSISSAUGA, ON, June 7, 2016 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2016 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated May 4, 2016 were elected as directors of the Company.

The detailed results of the votes by proxy are as follows:

Director Nominees	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	WITHHELD	FOR	WITHHELD
Daniel Chicoine	3,977,783	46,583	98.84%	1.16%
David A. Copeland	3,916,886	107,480	97.33%	2.67%
Anthony E. Dobranowski	3,917,205	107,161	97.34%	2.66%
John C. London	3,982,114	42,252	98.95%	1.05%
Dr. Jacques Messier	3,985,773	38,593	99.04%	0.96%
Samira Sakhia	3,987,856	36,510	99.09%	0.91%

About Nuvo Pharmaceuticals Inc.
Nuvo (TSX:NRI) is a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities.  Nuvo has three commercial products that are available in a number of countries; Pennsaid 2%, Pennsaid and the heated lidocaine/tetracaine patch.  Pennsaid 2% is sold in the U.S. by Horizon Pharma plc (NASDAQ:HZNP) and is available for partnering in certain other territories around the world.  Nuvo manufactures Pennsaid for the global market and Pennsaid 2% for the U.S. market at its FDA, Health Canada and EU approved manufacturing facility in Varennes, Québec.  For additional information, please visit www.nuvopharmaceuticals.com.

SOURCE Nuvo Pharmaceuticals Inc.

PLEASE CONTACT: Investor Relations, Email: [email protected]